17-AAG enhances the cytotoxicity of flavopiridol in mantle cell lymphoma via autophagy suppression

Neoplasma

Volumn 62, Issue 3, 2015, Pages 391-397

  Xiao, Y ^a   Guan, J ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

17 AAG; Autophagy; Flavopiridol; MCL

Indexed keywords

ACRIDINE ORANGE; BECLIN 1; FLAVOPIRIDOL; HEAT SHOCK PROTEIN 90; MITOGEN ACTIVATED PROTEIN KINASE; TANESPIMYCIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MANTLE CELL LYMPHOMA; PHOSPHORYLATION; WESTERN BLOTTING;

EID: 84969667384     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2015_047     Document Type: Article

References (33)

1. HARRIS N, JAFFE E, DIEBOLD J, FLANDRIN G, MULL-ER-HERMELINK H, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting. Journal of clinical oncology 1999; 17: 3835-3849.
2. ZUCCA E, STEIN H, COIFFIER B. European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL). Annals of oncology 1994; 5: 507-511.
3. MASSAGUE J. G1 cell-cycle control and cancer. Nature 2004; 432: 298-306. http: //dx. doi. org/10. 1038/nature03094
4. GRANT S, DENT P. Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: what's in a name? Molecular cancer therapeutics 2004; 3: 873-875.
5. LEE H, BAEK J, SHIN S, KWON S, CHA S, et al. Antitumor Effects of Flavopiridol on Human Uterine Leiomyoma In Vitro and in a Xenograft model. Reprod Sci 2014; 21: 1153-1160. http: //dx. doi. org/10. 1177/1933719114525266
6. HOFMEISTER C, POI M, BOWERS M, ZHAO W, PHELPS M, et al. A phase I trial of flavopiridol in relapsed multiple myeloma. Cancer chemotherapy and pharmacology 2014; 73: 249-257. http: //dx. doi. org/10. 1007/s00280-013-2347-y
7. HICKS M, HU Q, MACRAE E, DEWILLE J. JUNB promotes the survival of Flavopiridol treated human breast cancer cells. Biochemical and biophysical research communications 2014; 450: 19-24. http: //dx. doi. Org/10. 1016/j. bbrc. 2014. 05. 057
8. KITADA S, ZAPATA J, ANDREEFF M, REED J. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96: 393-397.
9. JONES J, RUPERT A, POI M, PHELPS M, ANDRITSOS L, et al. Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma. American journal of hematology 2014; 89: 19-24. http: //dx. doi. org/10. 1002/aih. 23568
10. BLACHLY J, BYRD J. Emerging drug profile: cyclin-dependent kinase inhibitors. Leukemia & lymphoma2013; 54: 2133-2143. http: //dx. doi. org/10. 3109/10428194. 2013. 783911
11. MAHONEY E, BYRD J, JOHNSON A. Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Autophagy 2013; 9: 434-435. http: //dx. doi. org/10. 4161/auto. 23027
12. MAHONEY E, LUCAS D, GUPTA S, WAGNER A, HERMAN S, et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood 2012; 120: 1262-1273. http: //dx. doi. org/10. 1182/blood-2011-12-400184
13. YUFU Y, NISHIMURA J, NAWATA H. High constitutive expression of heat shock protein 90 alpha in human acute leukemia cells. Leuk Res 1992; 16: 597-605. http: //dx. doi. org/10. 1016/0145-2126(92)90008-U
14. FERRARINI M, HELTAI S, ZOCCHI M, RUGARLI C. Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 1992; 51: 613-619. http: // dx. doi. org/10. 1002/ijc. 2910510418
15. XU C, LIU J, HSU L, LUO Y, XIANG R, et al. Functional interaction of heat shock protein 90 and Beclin 1 modulates Toll-like receptor-mediated autophagy. FASEB J 2011; 25: 2700-2710. http: //dx. doi. org/10. 1096/fj. 10-167676
16. COHEN-SAIDON C, CARMI I, KEREN A, RAZIN E. An-tiapoptotic function of Bcl-2 in mast cells is dependent on its association with heat shock protein 90beta. Blood 2006; 107: 1413-1420. http: //dx. doi. org/10. 1182/blood-2005-07-2648
17. SCHULTE T, BLAGOSKLONNY M, ROMANOVA L, MUSHINSKI J, MONIA BP, et al. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol Cell Biol 1996; 16: 5839-5845.
18. SEGUIN-PY S, CROIZIER S, CHAKRAMA F, DESPOUY G, LE GRAND J, et al. Identification of HSP90 as a new GABARAPL1 (GECl)-interacting protein. Biochimie 2012; 94: 748-758. http: //dx. doi. Org/10. 1016/j. biochi. 2011. ll. 006
19. SOLIT D, BASSO A, OLSHEN A, SCHER H, ROSEN N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003; 63: 2139-2144.
20. MCCOLLUM A, LUKASIEWICZ K, TENEYCK C, LINGLE W, TOFT DO, et al. Cisplatin abrogates the geldanamycin-induced heat shock response. Mol Cancer Ther 2008; 7: 3256-3264. http: //dx. doi. org/10. 1158/1535-7163. MCT-08-0157
21. YIN X, ZHANG H, LUNDGREN K, WILSON L, BURROWS F, et al. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer 2010; 126: 1216-1225.
22. TSE A, KLIMSTRA D, GONEN M, SHAH M, SHEIKH T, et al. A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin Cancer Res 2008; 14: 6704-6711. http: //dx. doi. org/10. 1158/1078-0432. CCR-08-1006
23. RAMALINGAM S, EGORIN M, RAMANATHAN R, REMICK S, SIKORSKI R, et al. A phase I study of 17-allylami-no-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clin Cancer Res 2008; 14: 3456-3461. http: //dx. doi. org/10. 1158/1078-0432. CCR-07-5088
24. MODI S, LINDEN H, SOLIT D, CHANDARLAPATY S, ROSEN N, et al. HSP90 inhibition is effective in breast cancer: a phase II trial oftanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011; 17: 5132-5139. http: //dx. doi. org/10. 1158/1078-0432. CCR-ll-0072
25. CHEN Y, AZAD M, GIBSON S. Methods for detecting autophagy and determining autophagy-induced cell death. Can J Physiol Pharmacol 2010; 88: 285-295. http: //dx. doi. org/10. 1139/Y10-010
26. MAIURI M, CRIOLLO A, TASDEMIR E, VICENCIO J, TAJEDDINE N, et al. BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy 2007; 3: 374-376. http: //dx. doi. org/10. 4161/auto. 4237
27. SOGA S, AKINAGA S, SHIOTSU Y. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr Pharm Des 2013; 19: 366-376. http: //dx. doi. org/10. 2174/138161213804143617
28. XIAO D, CHOI S, JOHNSON D, VOGEL V, JOHNSON C, et al. Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2. Oncogene 2004; 23: 5594-5606. http: //dx. doi. org/10. 1038/sj. one. 1207747
29. NI Z, WANG B, DAI X, DING W, YANG T, LI X, et al. HCC cells with high levels of Bcl-2 are resistant to ABT-737 via activation of the ROS-JNK-autophagy pathway. Free Radic BiolMed2014; 70: 194-203. http: //dx. doi. Org/10. 1016/j. freeradbiomed. 2014. 02. 012
30. YANG Z, KLIONSKY D. Eaten alive: a history of macro-autophagy. Nat Cell Biol 2010; 12: 814-822. http: //dx. doi. org/10. 1038/ncb0910-814
31. MAIURI M, ZALCKVAR E, KIMCHI A, KROEMER G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007; 8: 741-752. http: // dx. doi. org/10. 1038/nrm2239
32. STANCATO L, SILVERSTEIN A, OWENS-GRILLO J, CHOW Y, JOVE R, et al. The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase. J Biol Chem 1997; 272: 4013-4020. http: //dx. doi. org/10. 1074/jbc. 272. 7. 4013
33. EL-KHOURY V, PIERSON S, SZWARCBART E, BRONS N, ROLAND O, et al. Disruption of autophagy by the histone deacetylase inhibitor MGCDO103 and its therapeutic implication in B-cell chronic lymphocytic leukemia. Leukemia 2014; 28: 1636-1646. http: //dx. doi. org/10. 1038/leu. 2014. 19